Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

Summary

This phase 0 trial studies ixazomib citrate in treating patients with glioblastoma that has spread or returned after period of improvement who are planning to undergo surgery. When given by mouth, ixazomib may be able to reach tumor cells in the brain. Studying samples of tissue, blood, and plasma in the laboratory from patients receiving ixazomib may help doctors learn more about the effects of ixazomib on the cells. It may also help doctors understand how well patients will respond to treatment.

Timeline

Start

2016-03-24

Primary completion

2018-07-01

Completion

2020-09-03

Publications

• Quillin J, Patel R, Herzberg E, Alton D, Bikzhanova G, Geisler L, Olson J. A phase 0 analysis of ixazomib in patients with glioblastoma. Mol Clin Oncol. 2020 Nov;13(5):43. doi: 10.3892/mco.2020.2114. Epub 2020 Aug 13.

Drugs

Indications